

Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: *Post hoc* analysis from the pivotal Phase 3 (VANGUARD) study


E. Aygören-Pürsün,¹ P. Staubach,² T. J. Craig,^{3,4} T. Fukuda,⁵ R. Haki,^{6,7} J. Braverman,⁸ J.-P. Lawo,⁹ M. Pollen,⁸ C. Nenci,¹⁰ P. Li,¹¹ H. Farkas¹²

¹Klinikum der Johann Wolfgang-Goethe Universität, Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany; ²Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany; ³Allergy, Asthma and Immunology, Department of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; ⁴Vinmec International Hospital, Hanoi, Vietnam; ⁵Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan; ⁶Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic; ⁷Faculty of Medicine, Masaryk University, Brno, Czech Republic; ⁸CSL Behring, King of Prussia, PA, USA; ⁹CSL Behring Innovation GmbH, Marburg, Germany; ¹⁰CSL Behring AG, Bern, Switzerland; ¹¹Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong; ¹²Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary.

HAE AND GARADACIMAB¹⁻⁴

- HAE attacks are detrimental to HRQoL and potentially life-threatening^{1,2}
- Need for improved treatments to enhance disease control and “normalize” life^{1,2}
- Garadacimab is a first-in-class, fully human mAb targeting FXIIa under evaluation for HAE in pediatric, adolescent, and adult patients³⁻⁵

STUDY DESIGN AND KEY OUTCOMES OF THE PIVOTAL PHASE 3 (VANGUARD) STUDY⁴



87% Reduction in mean monthly number of HAE attacks vs placebo, P<0.0001 (median reduction 100%; exposure 6 months)

62% Attack-free for 6 months vs 0% with placebo

95% Responders* vs 33% with placebo

Favorable safety and tolerability profiles

Clinically meaningful HRQoL improvements as early as Day 31, sustained to Day 182


FOCUS OF THIS PRESENTATION

POST HOC ANALYSIS FROM THE PIVOTAL PHASE 3 STUDY

HRQoL per AE-QoL at Day 182 in patients who were attack-free vs placebo and those with ≥1 attack vs placebo

GARADACIMAB IMPROVED HRQOL VS PLACEBO

AE-QoL total score at Day 182, pivotal Phase 3 (VANGUARD) study*



AE-QoL MCID reached by 88% patients with garadacimab vs 55% with placebo, nominal P=0.004


MCID: ≥6 point improvement from baseline⁸

*Data are presented for patients with available AE-QoL data at Day 1 and Day 182; no patients receiving placebo remained attack-free.


GARADACIMAB DEMONSTRATED SUBSTANTIAL IMPROVEMENTS IN ALL AE-QOL DOMAINS VS PLACEBO

■ Never ■ Rarely ■ Occasionally ■ Often ■ Very often

AE-QoL scores by domain at Day 182 in garadacimab-treated patients*†




Functioning



Fatigue/mood

*Data are presented for patients with available AE-QoL data at Day 1 and Day 182; no patients receiving placebo remained attack-free; †Sum of AE-QoL total scores may exceed 100 due to rounding.

Nutrition



Fear/shame

CONCLUSIONS

- Garadacimab leads to substantial HRQoL improvement vs placebo
- The greatest HRQoL improvements vs placebo are observed with patients receiving garadacimab who are attack-free

AE-QoL, Angioedema Quality of Life questionnaire; FXIIa, activated factor XII; HAE, hereditary angioedema; HRQoL, health-related quality of life; mAb, monoclonal antibody; MCID, minimum clinically important difference; OLE, open-label extension; q1m, once-monthly; QoL, quality of life; SC, subcutaneous; SD, standard deviation.

References

1. Maurer M et al. *Allergy* 2022;77:1961–1990; 2. Busse PJ et al. *J Allergy Clin Immunol Pract* 2021;9:132–150.e3; 3. Cao H et al. *J Allergy Clin Immunol* 2018;142:1355–1358; 4. Craig TJ et al. *Lancet* 2023;401:1079–1090; 5. ClinicalTrials.gov. NCT05819775. Available at: <https://clinicaltrials.gov/ct2/show/NCT05819775> (accessed May 2024); 6. Bork K et al. *Allergy Asthma Clin Immunol* 2021;17:40; 7. Craig TJ et al. *J Allergy Clin Immunol Pract* 2019;7:1793–1802.e2; 8. Weller K et al. *Allergy* 2016;71:1203–1209.

Disclosures

The study was sponsored by CSL Behring. Medical writing support was provided by Helix, OPEN Health Communications, and funded by CSL Behring, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).